

CLAIM AMENDMENTS


Listing of Claims:

Claims 1-23 (canceled)

Claims 24-33 (canceled)

Claim 34 (not entered)

Claim 35 (new): A macrocyclic compound of the formula (1):




and it's pharmaceutically acceptable salts,

wherein


Fragment A₁ is:

(1-i)



wherein


Y is selected from the group consisting of



X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;

when X₁ is -CH-, R₁ is a radical independently selected from the group consisting of



Fragment A₂ is:


(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

Docket No. 6670/0H748




wherein

X_2 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_2 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_2 is absent;


when X_2 is $-\text{CH}-$, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)




wherein

X_3 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_3 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_3 is absent;


when X_3 is $-\text{CH}-$, R_3 is a radical independently selected from the group consisting of



W₁ to W₁₆ are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }




wherein (N) indicates the site of a covalent bond to the nitrogen atom of A₁ of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A₃ of formula (1).

Claim 36 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

Docket No. 6670/0H748




and it's pharmaceutically acceptable salts,

wherein



Fragment A₁ is:

(1-i)



wherein


Y is selected from the group consisting of



X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of



Fragment A₂ is:


{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

Docket No. 6670/0H748

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)




wherein

X_2 is $-CH-$, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;


when X_2 is $-CH-$, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)




wherein


X_3 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_3 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_3 is absent;


when X_3 is $-\text{CH}-$, R_3 is a radical independently selected from the group consisting of



W₁ to W₁₆ are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:



Fragment T is a radical selected from the group consisting of:




wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 37 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

Docket No. 6670/0H748




and it's pharmaceutically acceptable salts,

wherein

Fragment A₁ is:

(1-i)




wherein

X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;


when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;

when X₁ is -CH-, R₁ is a radical independently selected from the group consisting of:



Fragment A₂ is:

- (2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or
 (2-ii)




wherein

X_2 is -CH-, -(CH₂)₂- or -(CH₂)₃-;


when X_2 is -(CH₂)₂- or -(CH₂)₃-, R_2 is absent;

when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

- (3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or
 (3-ii)




wherein

X₃ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X₃ is -(CH₂)₂- or -(CH₂)₃-, R₃ is absent;

when X₃ is -CH-, R₃ is a radical independently selected from the group consisting of




Fragment T is a radical selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

Docket No. 6670/0H748



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A₁ of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A₃ of formula (1).